Dologen Tablet
NDC 52083-483
Product Information
Dologen (acetaminophen, dexbrompheniramine maleate) is a OTC MONOGRAPH DRUG-approved product labeled by Kramer Novis. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 52083-483 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
D
Code Structure Chart
Product Details
What is NDC 52083-483?
What are the uses of this product?
What are Active Ingredients of this product?
- ACETAMINOPHEN 500 mg/1 - Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
- DEXBROMPHENIRAMINE MALEATE 2 mg/1
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ACETAMINOPHEN (UNII: 362O9ITL9D)
- ACETAMINOPHEN (UNII: 362O9ITL9D) (Active Moiety)
- DEXBROMPHENIRAMINE MALEATE (UNII: BPA9UT29BS)
- DEXBROMPHENIRAMINE (UNII: 75T64B71RP) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)
- STEARIC ACID (UNII: 4ELV7Z65AP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2729424 - acetaminophen 500 MG / dexbrompheniramine maleate 2 MG Oral Tablet
- RxCUI: 2729424 - APAP 500 MG / dexbrompheniramine maleate 2 MG Oral Tablet
* Please review the full disclaimer at the bottom of this page.